Biomarin Pharmaceutical (BMRN) Total Debt Growth (1y) (2015 - 2023)
Biomarin Pharmaceutical (BMRN) Total Debt Growth (1y) (2015 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | 103.99% |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | 3.84% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | 0.07% |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Biomarin Pharmaceutical | 11.73 Bn | 9.51 Bn | 571.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 3,001.27% |
| Dec 31, 2022 | -66.98% |
| Sep 30, 2022 | -41.28% |
| Jun 30, 2022 | -6.98% |
| Mar 31, 2022 | 107.72% |
| Sep 30, 2021 | -87.12% |
| Jun 30, 2021 | -91.30% |
| Mar 31, 2021 | -91.58% |
| Sep 30, 2020 | 3,642.90% |
| Jun 30, 2020 | 3,628.59% |
| Mar 31, 2020 | 315.13% |
| Dec 31, 2019 | 321.03% |
| Sep 30, 2019 | -88.40% |
| Jun 30, 2019 | -87.02% |
| Mar 31, 2019 | 43.09% |
| Dec 31, 2018 | -76.19% |
| Mar 31, 2018 | 173.87% |
| Dec 31, 2017 | 679.13% |
| Mar 31, 2017 | -76.92% |
| Dec 31, 2016 | 106.10% |